Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Lunai Bioworks ( (LNAI) ) has issued an announcement.
Lunai Bioworks announced on October 16, 2025, that it has regained compliance with Nasdaq’s minimum bid price requirement, following a period where its stock price fell below the $1.00 threshold. The company achieved this compliance after maintaining a closing bid price of $1.00 or greater for eleven consecutive business days from September 30 to October 14, 2025. This milestone underscores Lunai Bioworks’ strategic execution and commitment to shareholder value, as it continues to focus on advancing its AI-powered platform in drug discovery and biodefense.
More about Lunai Bioworks
Lunai Bioworks Inc. is an AI-powered drug discovery and biodefense company pioneering safe and responsible generative biology. With proprietary neurotoxicity datasets, advanced machine learning, and a focus on dual-use risk management, Lunai is redefining how artificial intelligence can accelerate therapeutic innovation while safeguarding society from emerging threats.
Average Trading Volume: 333,883
Technical Sentiment Signal: Sell
Current Market Cap: $28.74M
For detailed information about LNAI stock, go to TipRanks’ Stock Analysis page.